CHICAGO -- Neoadjuvant chemotherapy failed to match upfront surgery for survival in resectable pancreatic cancer, a small randomized trial showed. Unexpectedly, patients assigned to surgery first ...

Patients with pancreatic cancer who received chemotherapy both before and after surgery experienced longer survival rates than would be expected from surgery followed by chemotherapy, according to a ...

Conversion Chemotherapy for Locally Advanced Pancreatic Carcinoma: FOLFIRINOX or Gemcitabine? The following represents disclosure information provided by authors of this manuscript. All relationships ...

Adjuvant combination leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin (FOLFIRINOX) and other multiagent chemotherapy regimens boost overall survival (OS) in patients with ...

The chemotherapy regimen known as FOLFIRINOX produces an "impressive clinical response" in locally advanced pancreatic ductal adenocarcinoma, according to the authors of a new small, retrospective, ...

Please provide your email address to receive an email when new articles are posted on . Patients who received the neoadjuvant regimen had similar median OS as those who received upfront surgery and ...

A new UCLA investigator-initiated study has found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic ...

Patients with pancreatic cancer who received chemotherapy both before and after surgery experienced longer survival rates than would be expected from surgery followed by chemotherapy, according to a ...